AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Core Insights - EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific antibody combination therapy approved for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy [1] - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 showed significantly superior progression-free survival and overall response rates compared to the standard of care R2, with approximately 75% of patients achieving a complete response [1] - This approval marks the third indication for EPKINLY and the first-ever FDA approval for a bispecific combination therapy in lymphoma [1] Company Insights - AbbVie (NYSE: ABBV) announced the FDA approval of EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma [1]